Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465003 | 0.90 | KMT2A (0.50) | HCAR2KMT2AMEN1ALDH1A1OPRM1 | |
| SCHEMBL11865726 | 0.87 | PDE4A (0.55) | HCAR2KMT2AKCNA3MEN1ALDH1A1 | |
| SCHEMBL4876849 | 0.87 | ADAM17 (0.50) | HCAR2KMT2AKCNA3MEN1ALDH1A1 | |
| SCHEMBL521247 | 0.87 | AKR1C1 (0.54) | HCAR2KMT2AMEN1ALDH1A1OPRM1 | |
| SCHEMBL7467608 | 0.87 | AKR1C1 (0.59) | KMT2AMEN1ALDH1A1OPRM1OPRD1 | |
| SCHEMBL8587542 | 0.85 | AKR1C1 (0.57) | KMT2AMEN1ALDH1A1OPRD1AKR1C1 | |
| SCHEMBL1626965 | 0.83 | ICMT (0.48) | HCAR2KMT2AMEN1ALDH1A1OPRM1 | |
| SCHEMBL21874215 | 0.83 | KDM1A (0.49) | HCAR2KMT2AMEN1ALDH1A1OPRM1 | |
| SCHEMBL11096445 | 0.82 | KMT2A (0.57) | KMT2AKCNA3MEN1ALDH1A1OPRM1 | |
| SCHEMBL4880472 | 0.81 | STS (0.42) | HCAR2KCNA3ALDH1A1SIGMAR1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4447454-A | Analgetic compounds, compositions and process of treatment | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4113866-A | ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | HCAR2 343/4885KMT2A 1132/4885KCNA3 1959/4885 |
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | HCAR2 68/4885KMT2A 1301/4885KCNA3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.